Recombinant Human BTNL9 Protein (Ser35-Lys256), C-Fc-tagged

Product Description

Cat

IMP-10172

Official Symbol

BTNL9

Product Overview

Recombinant human BTNL9 protein (Ser35-Lys256) with a human IgG1 (Pro100-Lys330) Fc tag at C-terminus was expressed in human embryonic kidney cell.

Description

Predicted to enable signaling receptor binding activity. Predicted to be involved in T cell receptor signaling pathway and regulation of cytokine production. Predicted to be located in plasma membrane. Predicted to be active in external side of plasma membrane.

Expression System

HEK293

Species

Human

Tag

C-Fc

Predicted N Terminal

Ser35

Form

Lyophilized from a 0.2 μm filtered solution in PBS.

Molecular Mass

Predicted Molecular Mass: 52 kDa
SDS-PAGE: 60-69 kDa, reducing conditions

Protein length

Ser35-Lys256

Bio-activity

Measured by its ability to inhibit anti-CD3 antibody induced IFN-gamma secretion by human peripheral blood mononuclear cells (PBMC). The ED50 fot this effect is 3-15 μg/mL.

Endotoxin

<0.10 EU/μg of the protein by the LAL method.

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie Blue Staining.

Notes

Disulfide-linked homodimer

Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70 centigrade as supplied.
1 month, 2 to 8 centigrade under sterile conditions after reconstitution.
3 months, -20 to -70 centigrade under sterile conditions after reconstitution.

Reconstitution

Reconstitute at 200 μg/mL in PBS.

Bioactivity-ELISA 1

Measured by its ability to inhibit anti-CD3 antibody induced IFN-gamma secretion by human peripheral blood mononuclear cells (PBMC). The ED50 fot this effect is 3-15 μg/mL.

Data Sheet MSDS

Datasheet MSDS

For research or industrial raw materials, not for personal medical use!

Online Inquiry